On 13 December at 16:00, join us for a virtual roundtable where an expert panel of clinicians and basic researchers will discuss the promising Phase III trial data of lecanemab for the treatment of Alzheimer’s disease, following presentation of results at CTAD.
More info
Amyotrophic Lateral Sclerosis (ALS), or Motor Neurone Disease (MND), is a fatal neurodegenerative condition that causes progressive weakness of the muscles due to the degeneration of motor neurones in the brain and spinal cord. Many of our pioneering research programmes are committed to finding much-needed treatments for those people affected now and in the future.
Read more
After six years as Director of the UK DRI, Prof Bart De Strooper is stepping down to focus on his research.
Read more
Co-founded by Prof Chris Shaw (UK DRI at King's), AviadoBio will use a patented gene therapy platform to develop innovative treatments for people living with neurodegenerative diseases. If successful, these treatments have the potential to permanently correct faulty genes, transforming the lives of individuals affected.
Read more
The Dementia UK Ecosystem (DUKE) brings together leaders from the UK DRI, Dementias Platform UK, the National Institute for Health Research, the pharmaceutical industry, and funders to create a cohesive community, coordinating efforts to accelerate progress in tackling dementia.
Read more
Group Leader Dr Nir Grossman (UK DRI at Imperial) is leading a new trial using deep electrical currents applied to the brain of people living with Alzheimer's disease. The team are recruiting participants over the next year.
Read more
We have a clearly defined vision at the UK DRI to develop effective therapeutics, diagnostics and technologies for people living with dementia. Alongside building our disease knowledge over the coming years, we will also make progress in translating these discoveries into the clinic.
Translation and innovation
We accelerate, innovate, deepen and broaden discovery science in dementia, with the goal of filling the huge knowledge gap in this field. We exist to bring forward the day when research benefits people living with and those at risk of dementia.
Read our science vision
Our efforts to increase the diversity of our team, ensure inclusion and promote equality of opportunity, align with our vision for the UK DRI’s Institute culture and identity as a world-leader in dementia research.
Equity, Diversity and Inclusion
We study a range of neurodegenerative disorders that cause dementia. Many of them share fundamental disease mechanisms and characteristics, and greater understanding gained in one can often benefit others. To ensure we capitalise on diverse expertise, approaches and perspectives, we have established cross-centre themes.
Research themes
